

# ForPatients

by Roche

Metastatic Prostate Cancer Advanced Prostate Cancer

## A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer

**Trial Status**  
Recruiting

**Trial Runs In**  
1 Countries

**Trial Identifier**  
NCT07567846 GO46445

---

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

### *Trial Summary:*

The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-1261 in participants with advanced or metastatic prostate cancer. It's also to identify a recommended dose(s) and regimen for GDC-1261 for subsequent studies.

**Genentech, Inc.**  
Sponsor

**Phase 1/Phase 2**  
Phase

---

**NCT07567846 GO46445**  
Trial Identifiers

---

### *Eligibility Criteria:*

**Gender**  
Male

**Age**  
>=18 Years

**Healthy Volunteers**  
No

---